Beijing DP Technology is a pioneer in AI-driven scientific innovation, leveraging its cutting-edge "AI for Science" approach to accelerate breakthroughs across pharmaceuticals, energy, and materials science. The DP Particle Universe integrates advanced pre-trained models with specialized platforms like Hermite® for drug design and Piloteye® for battery development, bridging research with industrial applications. By combining AI-powered tools with an open scientific ecosystem, DP is redefining how industries solve complex R&D challenges and bring discoveries to market faster.
Location: China, Beijing
Employees: 51-200
Investors 5
| Date | Name | Website |
| 20.05.2026 | Vision Cap... | visionplus... |
| 10.07.2026 | Source Cod... | sourcecode... |
| 09.02.2022 | Matrix Par... | matrixpart... |
| 10.07.2026 | Magic Ston... | msacap.com |
| 12.01.2024 | Qiming Ven... | qimingvc.c... |
Mentions in press and media 19
| Date | Title | Description |
| 20.08.2025 | SciMaster Leads the Scientific Agent Revolution in the AI Scientist Era | Share Share Share Share Email Shanghai JiaoTong University, DP Technology, and the Institute for Advanced Algorithms Research (Shanghai) jointly introduces SciMaster, the World’s First “Universal Research Intelligence Agent”, committed to p... |
| 09.01.2025 | RiDYMO® Designs Cyclic Peptide for "Undruggable" β-Catenin Target Within Two Months | BEIJING, Jan. 9, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically "undruggable" protein, in just two months... |
| 19.11.2024 | RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development | BEIJING, Nov. 19, 2024 /PRNewswire/ -- With the support of the RiDYMO® platform, we are able to comprehensively explore various potential targets in drug development, including protein-protein interactions, kinases, GPCRs, ion channels, and... |
| 14.10.2024 | Deals in brief: Tin Men Capital leads GlobalTix’s Series B round, WhiteCoat acquires Good Doctor, ten China deals, and more | GlobalTix raises SGD 6.5 million to expand AI-driven tourism solutions Singapore-based GlobalTix, a ticketing software provider and marketplace distribution platform for the tourism industry, has closed a SGD 6.5 million (USD 5 million) Ser... |
| 03.08.2024 | Unraveling the Secrets of GPX4: A New Era in Ferroptosis Research | Ferroptosis is a term that’s gaining traction in the scientific community. It’s a form of cell death that’s as intricate as a spider’s web. At the heart of this process lies glutathione peroxidase 4 (GPX4), a protein that plays a pivotal ro... |
| 01.08.2024 | Novel Non-Covalent Hits Against GPX4 Identified Using the RiDYMO® Reinforced Dynamics Platform of DP Technology | Research on ferroptosis is gaining momentum, but the development of small molecule inhibitors faces numerous challenges BEIJING, Aug. 1, 2024 /PRNewswire/ -- Glutathione peroxidase 4 (GPX4) is recognized as a critical regulator of ferroptos... |
| 01.08.2024 | Novel Non-Covalent Hits Against GPX4 Identified Using the RiDYMO® Reinforced Dynamics Platform of DP Technology | Research on ferroptosis is gaining momentum, but the development of small molecule inhibitors faces numerous challenges BEIJING, Aug. 1, 2024 /PRNewswire/ -- Glutathione peroxidase 4 (GPX4) is recognized as a critical regulator of ferroptos... |
| 08.07.2024 | DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Lp-PLA2 Inhibitor for DR and DME | The nomination of novel Lp-PLA2 inhibitor DPT0415 for the treatment of DR & DME. DPT0415 is a highly potent, selective and safe Lp-PLA2 inhibitor with sufficient target engagement at a dose of 0.3 mpk and robust efficacy in the STZ-indu... |
| 08.07.2024 | DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Lp-PLA2 Inhibitor for DR and DME | The nomination of novel Lp-PLA2 inhibitor DPT0415 for the treatment of DR & DME. DPT0415 is a highly potent, selective and safe Lp-PLA2 inhibitor with sufficient target engagement at a dose of 0.3 mpk and robust efficacy in the STZ-indu... |
| 08.07.2024 | DP Technology Announces Nomination of Development Candidate, a CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer's Disease | BEIJING, July 8, 2024 /PRNewswire/ -- DP Technology, an "AI for Science" paradigm-driven company, today announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-PLA2, as a preclinical candidate for t... |
Show more